In the Vinony graph
Within Vinony's link graph, efgartigimod alfa is referenced by 169 other articles, and connects out to lumiliximab, medication and public domain.
It is catalogued under topics including Chemical pages without ChemSpiderID, Drugs with non-standard legal status and Infobox drug articles without a structure image.
Its subject is documented across 6 Wikipedia language editions.
Medication
- Generic name
- Efgartigimod Alfa And Hyaluronidase (Human Recombinant)
- Brand names
- Vyvgart Hytrulo
- Drug class
- Endoglycosidase, Neonatal Fc Receptor Blocker, Neonatal Fc Receptor Blockers
- Route
- Subcutaneous
- Type
- Human Prescription Drug
- Manufacturer
- argenx US
Indications: 1 INDICATIONS AND USAGE VYVGART HYTRULO is indicated for the treatment of adult patients with: generalized myasthenia gravis (gMG) chronic inflammatory demyelinating polyneuropathy (CIDP) VYVGART HYTRULO is a combination of efgartigimod alfa, a neonatal Fc receptor blocker, and hyaluronidase, an… (per FDA label)
Sources: openFDA · RxNorm (NLM). Not medical advice.
Clinical Trials
2 registered- RECRUITINGA Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfaargenx · NCT06298565
- PHASE2RECRUITINGEfgartigimod for the Treatment of Acute Optic NeuritisAnastasia Vishnevetsky, MD, MPH · NCT06453694
Wikidata facts
- Instance of
- antibody
Show 1 more fact
- medical condition treated
- myasthenia gravis
via Wikidata · CC0
Connections
lumiliximab
Entity
medication
Entity
public domain
Entity
digital object identifier
Entity
chemical formula
Entity
antibody
Entity
molar mass
Entity
PubMed
Entity
T-lymphocytes
Entity
myasthenia gravis
Entity
interferon
Entity
CAS Registry Number
Entity
United States Food and Drug Administration
Entity
thalidomide
Entity
Anatomical Therapeutic Chemical Classification System
Entity
MedlinePlus
Entity
intravenous infusion and defusion
Entity
European Medicines Agency
Entity
methotrexate
Entity
monoclonal antibody
Entity